Treatment of epilepsy in the elderly

Progress in Neurobiology

Volumn 58, Issue 5, 1999, Pages 389-407

  Gareri, Pietro ^a   Gravina, Tiziana ^a   Ferreri, Guido ^a   De Sarro, Giovambattista ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; VALPROIC ACID; VIGABATRIN;

AGED; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG EFFICACY; DRUG METABOLISM; DRUG TOLERABILITY; DRUG USE; EPILEPSY; KIDNEY FUNCTION; LIVER FUNCTION; PATIENT COMPLIANCE; PHYSIOLOGY; POLYPHARMACY; PRIORITY JOURNAL; REVIEW;

ADULT; AGED; AGED, 80 AND OVER; AGING; ANTICONVULSANTS; DRUG INTERACTIONS; EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, GABA-A; RECEPTORS, GLUTAMATE;

EID: 0033001319     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-0082(98)00089-6     Document Type: Review

References (170)

1. Albright P.S., Bruni J. Effects of carbamazepine and its epoxide and metabolites on amygdala-kindled seizures in rats. Neurology. 34:1984;1383-1386.
2. Baltzer, V. and Schmutz, M. (1977) Experimental anticonvulsant properties of GP 47 680 and of GP 47 779, its main human metabolite; compounds related to carbamazepine. In: Advances in Epileptology, pp. 295-299, Eds H. Meinardi and A. J. Rowan. Swets and Zeitlinger, New York.
3. Bauer L.A., Blouin R.A. Age and phenytoin kinetics in adult epileptics. Clin. Pharmacol. Ther. 31:1982;301-304.
4. Bauer L.A., Davis R., Wilensky A., Raisys V.A., Levy R.H. Valproic acid clearance: unbound fraction and diurnal variations in young and elderly adults. Clin. Pharmacol. Ther. 37:1985;697-700.
5. Beck, L. H. and Burkart, J. M. (1990) Aging changes in renal function. In: Principles of Geriatric Medicine and Gerontology, pp. 555-564, Eds R. Anders, E. L. Biermen and J. P. Bless. McGraw-Hill, New York.
6. Beers M.H., Ouslander J.G. Risk factors in geriatric drug prescribing. Drugs. 37:1989;105-112.
7. Bender A.D., Post A., Meier J.P., Higson J.E., Reichard G. Jr. Plasma protein binding of drugs as a function of age in adult human subjects. J. Pharm. Sci. 64:1975;1711-1713.
8. Betts T., Goodwin G., Withers R.M., Yuen A.W. C. Human safety of lamotrigine. Epilepsia. 32:1991;S17-S21.
9. Bialer M. Comparative pharmacokinetics of the newer antiepileptic drugs. Clin Pharmacokinet. 24:1993;441-452.
10. Bialer M., Johannessen S.I., Kupferberg H.J., Levy R.H., Loiseau P., Perucca E. Progress report on new antiepileptic drugs: a summary of the Third Eilat Conference. Epilepsy Res. 25:1996;299-319.
11. Bourgeois B.F. D., Wad N. Individual and combined antiepileptic and neurotoxic activity of carbamazepine and carbamazepine-10,11-epoxide in mice. J. Pharm. Exp. Ther. 231:1984;411-415.
12. Bourgeois B., Leppik I.E., Sackellares J.C. Felbamate: a double-blind controlled trial in patients undergoing presurgical evaluation of partial seizures. Neurology. 43:1993;693-696.
13. Boyd R.A., Bockbrader H.N., Turck D., Sedman A.J., Posvar E.L., Chang T. Effect of subject age on the single dose pharmacokinetics of orally administered gabapentin (CI-945). Pharm Res. 9:1990;S215.
14. 3H) diazepam binding. Proc. Natl Acad. Sci. USA. 74:1977;3805-3809.
15. Brodie M.J. Drug interactions in epilepsy. Epilepsia. 33(Suppl. 1):1992;S13-S22.
16. Brodie M.J. Lamotrigine. Lancet. 339:1992;1397-1400.
17. Brodie M.J., Richens A., Yuen A.W. Double blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. U.K. Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet. 345:1995;476-479.
18. Bruce A., Andersson M., Arvidsson B., Isaksson B. Body composition: prediction of normal body potassium, body water and body fat in adults on the basis of body height, body weight and age. Scand. J. Clin. Lab. Invest. 40:1980;461-473.
19. Bryson S.M., Verma N., Scott P.J. W., Rubin P.C. Pharmacokinetics of valproic in young and elderly subjects. Br. J. Clin. Pharmacol. 16:1983;104-105.
20. Castelden C.M., George C.F., Marcer D., Rallett C. Increased sensitivity to nitrazepam in old age. Br. Med. J. 1:1977;10-12.
21. Chadwick D. Gabapentin. Lancet. 343:1994;89-91.
22. Christe W., Kramer G., Vigonius U., Pohlmann H., Steinhoff B.J., Brodie M.J., Moore A. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res. 26:1997;451-460.
23. Clark D.W. J. Genetically determined variability in acetylation and oxidation: therapeutic implications. Drugs. 29:1985;342-375.
24. Cloyd J.C., Lackner T.E. Antiepileptic drugs in the elderly: pharmacoepidemiology and pharmacokinetics. Arch. Family Med. 7:1994;589-598.
25. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron. 16:1976;31.
26. Cohen A., Lancman M., Mogul H., Marks S., Smith K. Strategies to protect bone mass in the older patient with epilepsy. Geriatrics. 52:1997;70-81.
27. Comstock T.J., Sica D.A., Bockbrader H.N., Underwood B.A., Selman A.J. Gabapentin pharmacokinetics in subjects with various degrees of renal function. J. Clin. Pharmacol. 30:1990;862.
28. Cook P.J., Flanagan R., James I.M. Diazepam tolerance: effect of age, regular sedation and alcohol. Br. Med. J. 289:1984;351-353.
29. de la Court A., Breteler M.M. B., Meinardi H., Hauser W.A., Hofman A. Prevalence of epilepsy in the elderly: the Rotterdam Study. Epilepsia. 37:1996;141-147.
30. Crawford P., Ghadiali E., Lane R., Blumhardt L., Chadwick D. Gabapentin as an antiepileptic drug in man. J. Neurol. Neuros. Psychiat. 50:1987;682-686.
31. Crooks J., Stevenson I.H. Drug response in the elderly sensitivity and pharmacokinetic considerations. Age Ageing. 10:1981;73-80.
32. Curran H.V., Java R. Memory and psychomotor effects of oxcarbazepine in healthy human volunteers. Eur. J. Clin. Pharmacol. 44:1993;529-533.
33. Cusack B.J. Drug metabolism in the elderly. J. Clin. Pharmacol. 28:1988;571-576.
34. Dam A.M., Fuglsang-Frederiksen A., Svarre-Olsen U., Dam M. Late onset epilepsy: etiologics, types of seizures, and value of clinical investigation, EEG and computerized tomography scan. Epilepsia. 26:1985;227-231.
35. Dam M. Oxcarbazepine in monotherapy. Behav. Neurol. 3:1990;31-34.
36. Dam M., Ekberg R., Loyning Y., Waltimo O., Jakobsen K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res. 3:1989;70-76.
37. Davis R., Peters D.H., McTavish D. Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs. 47:1994;332-372.
38. Dawling S., Crome P. Clinical pharmacokinetic considerations in the elderly. Clin. Pharmacokinet. 17:1989;236-263.
39. Dickinson R.G., Hooper W.D., Dunstan P.R., Eadie M.J. First dose and steady-state pharmacokinetics of oxcarbazepine and its 10-hydroxy-metabolite. Eur. J. Clin. Pharmacol. 37:1989;69-74.
40. Drinka P.J., Miller J., Voeks S.K., Hamel P. Phenytoin binding in a nursing home geriatric patient population. J. Geriatr. Drug Ther. 3:1988;73-82.
41. Drury I., Beydoun A. Seizures and epilepsy in the elderly revisited. Arch. Intern. Med. 158:1998;99-100.
42. Eadie M.J., Lander C.M., Hooper W.D., Tyrer J.H. Factors influencing plasma phenobarbitone levels in epileptic patients. Br. J. Clin. Pharmacol. 4:1977;541-547.
43. Evans J.G., Jarvis E.H. Nitrazepam and the elderly. Br. Med. J. 4:1972;487.
44. Everitt A.D., Sander J.W. Incidence of epilepsy is now higher in elderly people than children. Br. Med. J. 316:1998;780.
45. Faigle J.W., Menge G.P. Pharmacokinetic and metabolic features of oxcarbazepine and their clinical significance: comparison with carbamazepine. Int. Clin. Psychopharmacol. 5:1990;S73-S82.
46. Faught E., Sachdeo R.C., Remler M.D. Felbamate monotherapy for partial-onset seizures: an active-control trial. Neurology. 43:1993;688-692.
47. Fischer J.H., Barr A.N., Rogers S.L., Fischer P.A., Trudeau V.L. Lack of serious toxicity following gabapentin over-dose. Neurology. 44:1984;982-983.
48. Fisher, R. S. and Kerrigan, J. F. (1995) Vigabatrin: toxicity. In: Antiepileptic Drugs, 4th Edn, pp. 931-939, Eds R. H. Levy, R. H. Mattson and B. S. Meldrum. Raven Press, New York.
49. Forbes G.B., Reina J.C. Adult lean body mass declines with age: some longitudinal observations. Metabolism. 19:1970;653-663.
50. Forsgren L. Prevalence of epilepsy in adults in Northern Sweden. Epilepsia. 33:1992;450-458.
51. Friedman J.R., Norman D.C., Yoshikawa T.T. Correlation of estimated renal function parameters versus 24-hour creatinine clearance in ambulatory elderly. J. Am. Geriatric. Soc. 37:1989;145-149.
52. Galeotta G., Paoletti V., Mammarella A., Falaschi R. La terapia farmacologica nel paziente anziano. Clin. Ter. 135:1990;181-192.
53. Gareri P., Stilo G., Bevacqua I., Mattace R., Ferreri G., De Sarro G.B. Antidepressant drugs in the elderly: a review. Gen. Pharmacol. 30:1998;465-475.
54. Goa K.L., Sorkin E.M. Gabapentin: a review of its pharmacological properties and clinical potential in epilepsy. Drugs. 46:1993;409-427.
55. Goa K.L., Ross S.R., Chrisp P. Lamotrigine: a review of its pharmacological properties and clinical efficacy in epilepsy. Drugs. 46:1993;152-176.
56. Godfrey J. Epilepsy in the elderly. Postgrad Med. J. 63:1987;1069-1070.
57. Gonzalez F.J., Skoda R.C., Kinenza S. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature (Lond.). 331:1988;442-446.
58. Goodridge D.M. G., Shorvon S.D. Epileptic seizures in a population of 6000. Br. Med. J. 287:1983;641-647.
59. Granieri E., Rosati G., Tola R., Pavoli M., Paolino E., Pinna L., Monetti V.C. A descriptive study of epilepsy in the district of Copparo, Italy, 1964-1978. Epilepsia. 24:1983;502-514.
60. Grant S.M., Heel R.C. Vigabatrin: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in epilepsy and disorders of motor control. Drugs. 41:1991;889-926.
61. Graves N.M., Holmes G.B., Fuerst R.H., Leppik I.E. Effect of felbamate on phenytoin and carbamazepine serum concentrations. Epilepsia. 30:1989;225-229.
62. Greenblatt D.J., Allen M.D., Locniskar A., Harnatz J.S., Shader R.I. Lorazepam Kinetics in the elderly. Clin. Pharmacol. Ther. 26:1979;103-113.
63. Greenblatt D.J., Allen M.D., Harmatz J.S., Shader R.I. Diazepam disposition determinants. Clin. Pharmacol. Ther. 27:1980;301-312.
64. Greenblatt D.J., Sellers E.M., Shader R.I. Drug disposition in old age. N. Engl. J. Med. 306:1982;1081-1088.
65. Greenblatt D.J., Abernethy D.R., Shader R.I. Pharmacokinetic aspects of drug therapy in the elderly. The Drug Monit. 8:1986;249-255.
66. Haerer A.F., Anderson D.W., Schoenberg B.S. Prevalence and clinical features of epilepsy in a biracial United States population. Epilepsia. 27:1986;66-75.
67. Haley C.J., Nelson J. Phenytoin-enteral feeding interaction. Drug Intell. Clin. Pharm. 23:1989;796-798.
68. Hamilton M.J., Cohen A.F., Yuen A.W. C., Harkin N., Land G., Weatherley B.C., Peck A.W. Carbamazepine and lamotrigine in healthy volunteers: relevance to early tolerance and clinical trial dosage. Epilepsia. 34:1993;166-173.
69. Hauser W.A. Seizure disorders: the changes with age. Epilepsia. 33:1992;S6-S14.
70. Hauser W.A., Kurland L.T. The epidemiology of epilepsy in Rochester, Minnesota, 1935 through 1967. Epilepsia. 16:1975;1-66.
71. Hauser W.A., Ng S.K. C., Brust J.C. M. Alcohol, seizures and epilepsy. Epilepsia. 29:1988;S66-S78.
72. Hauser W.A., Annegers J.F., Kurland L.T. Prevalence of epilepsy in Rochester, Minnesota, 1940-1980. Epilepsia. 31:1991;429-445.
73. 3H]gabapentin to a novel site in rat brain: autoradiografic studies. Eur. J. Mol. Pharmacol. 244:1993;303-309.
74. Hockings N., Pall A., Moody A.P. J., Divdson A.V. M., Davidson D.L. W. The effects of age on carbamazepine pharmacokinetics and adverse effects. Br. J. Clin. Pharmacol. 22:1986;725-728.
75. Houtkooper M.A., Lammertsma A., Meyer J.W. A., Goedhart D.M., Meinardi H., van Oorschot C.A., Blom G.F., Hopener R.J., Hulsman J.A. Oxcarbazepine (GP 47 680): a possible alternative to carbamazepine? Epilepsia. 28:1987;693-698.
76. Hulihan J.F. Seizures in special populations. Children, the elderly, and patients with coexistent medical illness. Postgrad Med. 102:1997;165-168.
77. Jallon P. L'épilepsie de l'adulte et du sujet agé Schweiz. Rundsch. Med. Prax. 83:1994;1126-1131.
78. Johannessen A.C., Nielsen O.A. Hyponatremia induced by oxcarbazepine. Epilepsy Res. 1:1987;155-156.
79. Jones, G. L. and Wimbihsh, G. H. (1985) Phenytoin. In: Handbook of Experimental Pharmacology, Vol. 4, pp. 195-226, Eds. H. H. Frey and D. Janz. Raven Press, New York.
80. Kalviainen R., Aikia M., Riekkinen P.J. Cognitive adverse effects of antiepileptic drugs: incidence, mechanisms and therapeutic implications. CNS Drugs. 5:1996;358-368.
81. Klosterskov Jensen P., Saano V., Haring P., Svenstrup B., Menge G.P. Possible interaction between oxcarbazepine and an oral contraceptive. Epilepsia. 33:1992;1149-1152.
82. Kramer G. Characteristics of pharmacotherapy of epilepsy in the elderly. Schweiz Rundsch Med. Prax. 86:1997;1418-1423.
83. Kristensen O., Klitgaard N.A., Jonsson B., Sindrup S. Pharmacokinetics of 10-OH-carbamazepine, the main metabolite of the antiepileptic oxcarbazepine, from serum and saliva concentrations. Acta Neurol. Scand. 68:1983;145-150.
84. Kumps A., Wurth C. Oxcarbazepine disposition: preliminary observations in patients. Biopharm. Drug Dispos. 11:1990;365-370.
85. Kutt H. Interactions between anticonvulsants and other commonly prescribed drugs. Epilepsia. 25:1984;S118-S131.
86. Kutt H., Waters L., Fouts J.R. The effects of some stimulators (inducers) of hepatic microsomal drug-metabolizing enzyme activity on substrate-induced difference spectra in rat liver microsomes. J. Pharmacol. Exp. Ther. 176:1971;11-26.
87. Lamy P.P. Geriatric drug therapy. Am. Fam. Phys. 34:1986;118-124.
88. Lang D.G., Wang C.M., Cooper B.R. Lamotrigine, phenytoin and carbamazepine interactions on the sodium current present in N4TG1 mouse neuroblastoma cells. J. Pharmacol. Exp. Ther. 266:1993;829-835.
89. Lannon S.L. Epilepsy in the elderly. J. Neurosci. Nurs. 25:1993;273-282.
90. Leach M.J., Marden C.M., Miller A.A. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia. 27:1986;490-497.
91. Leach M.J., Baxter M.G., Critchley M.A. E. Neurochemical and behavioral aspects of lamotrigine. Epilepsia. 32:1991;S4-S8.
92. Leppik I.E. Metabolism of antiepileptic medication: newborn to elderly. Epilepsia. 33:1992;S32-S40.
93. Leppik I.E., Dreifuss F.E., Pledger G.W. Felbamate for partial seizures: results of a controlled clinical trial. Neurology. 41:1991;1785-1789.
94. Lesser R.P., Luders H.D., Dinner D.S., Morris H.H. Epileptic seizures due to thrombotic and embolic cerebrovascular disease in older patients. Epilepsia. 26:1985;622-630.
95. Linnoila M., Viukari M. Efficacy and side-effects of nitrazepam and thioridazine as sleeping aids in psychogeriatric inpatients. Br. J. Psychiat. 128:1976;566-569.
96. Lloyd, G. K. and Gillenwater, G. (1997) Epilepsy and antiepileptic drugs. In: Principles of Pharmacology, pp. 363-393, Eds. P. L. Munson, R. A. Mueller and G. R. Breese. Chapman and Hall, New York.
97. Loiseau J., Loiseau P., Duché B., Guyot M., Dartigues J.F., Aublet B. A survey of epileptic disorders in southwest France: seizures in elderly patients. Ann. Neurol. 27:1990;232-237.
98. Loscher W., Nau H. Pharmacological evaluation of various metabolites and analogues of valproic acid: anticonvulsivant and toxic potencies in mice. Neuropharmacology. 24:1985;427-435.
99. Loscher W., Nau H., Marescaux C., Vergrus M. Comparative evaluation of anticonvulsant and toxic potencies of valproic acid and 2-en valproic acid in different animal models. Eur. J. Pharmacol. 2:1984;211-218.
100. Luhdorf K., Jensen L.K., Plesner A. Ethiology of seizures in the elderly. Epilepsia. 27:1986;458-463.
101. Manji F., Fejerskov O., Baelum V. Pattern of dental caries in an adult rural population. Caries Res. 23:1989;55-62.
102. Martines C., Gatti G., Sasso E., Calzetti S., Perucca E. The disposition of primidone in elderly patients. Br. J. Clin. Pharmacol. 30:1990;607-611.
103. Matsuo F., Bergen D., Faught E. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. Neurology. 43:1993;693-696.
104. Mayersohn M. The "xylose test" to assess gastrointestinal absorption in the elderly, a pharmacokinetic evaluation of the literature. J. Gerontol. 37:1982;300-305.
105. McDowell, F. H. (1992). Antiepileptic drugs in the elderly. In: Medical Treatment of Epilepsy, pp. 65-71, Ed. S. R. Resor. Marcel Dekker, New York.
106. McCabe R.T., Wasterlain C.G., Kucharczy N., Sofia R.D., Vogel J.R. Evidence for anticonvulsant and neuroprotectant action of felbamate mediated by strychnine-insensitive glycine receptors. J. Pharmacol. Exp. Ther. 264:1993;1248-1252.
107. McLean, M. J. (1995) Gabapentin. Chemistry, absorption, distribution and excretion. In: Antiepileptic Drugs, 4th Edn, pp. 843-849. Eds. R. H. Levy, R. H. Mattson and B. S. Meldrum. Raven Press, New York.
108. McLean M.J., Macdonald R.L. Sodium valproate, but not ethosuximide, produces use and voltage-dependent limitation of rapidly firing action potentials of mouse central neurons in cell culture. J. Pharmacol. Exp. Ther. 237:1986;1001-1011.
109. Meldrum B. Action of established and novel anticonvulsant drugs on the basic mechanisms of epilepsy. Epilepsy Res. 11(Suppl.):1996;67-77.
110. Messenheimer J.A. Lamotrigine. Epilepsia. 36:1995;S87-S94.
111. Messenheimer J.A., Ramsay R.A., Willmore L.J. Lamotrigine therapy for partial seizures: a multicenter placebo-controlled, double-blind, crossover trial. Epilepsia. 35:1994;113-121.
112. Montamat S.C., Cusack B.J., Yestal R.E. Management of drug therapy in the elderly. N. Engl. J. Med. 321:1989;303-309.
113. Morselli, P. L. and Rossi, L. (1982) Carbamazepine absorption, distribution and excretion. In: Antiepileptic Drugs, 2nd Edn, pp. 465-482, Eds. D. M. Woodbury, J. K. Penry and C. E. Pippenger. Raven Press, New York.
114. Norman T.R., Burrows G.D. Plasma concentrations of benzodiazepines. A review of clinical findings and implications. Prog. NeuroPsychopharmacol.Biol. Psychiatry. 8:1984;115-126.
115. Ojemann L.M., Wilensky A.J., Emkin N.R., Chmelir T., Ricker B.A., Wallace J. Long term treatment with gabapentin for partial epilepsy. Epilepsy Res. 13:1992;159-165.
116. Pan H.Y., Hoffman B.B., Pershe R.A., Blascke T.F. Decline in β-adrenergic receptor-mediated vascular relaxation with aging in man. J. Pharmacol. Exp. Ther. 239:1986;802-807.
117. Patsalos P.N., Duncan J.S. Antiepileptic drugs. A review of clinically significant drug interactions. Drug Safety. 9:1993;156-184.
118. Peck A.W. Clinical pharmacology of lamotrigine. Epilepsia. 32:1991;S9-S12.
119. Pellock J.M. Carbamazepine side effects in children and adults. Epilepsia. 28:1987;S64-S70.
120. Pellock J.M., Willmore L.J. A rational guide to routine blood monitoring in patients receiving antiepileptic drugs. Neurology. 41:1991;961-964.
121. Perucca E., Bialer M. The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. Clin. Pharmacokinet. 31:1996;29-46.
122. Perucca E., Grimaldi R., Gatti G., Pirracchio S., Crema F., Frigo G.M. Pharmacokinetics of valproic acid in the elderly. Br. J. Clin. Pharmacol. 17:1984;665-669.
123. Porter, R. J. (1986) Recognizing and classifying epileptic seizures and epileptic syndromes. In: Neurologic Clinics: Epilepsy, pp. 161-179, Eds. R. J. Porter and W. H. Theodore. Saunders, London.
124. Porter, R. J. (1993) Classification of epileptic seizures and epileptic syndromes. In: A Textbook of Epilepsy, pp. 1-22. Eds. J. Laidlaw, A. Richens and D. Chadwick. Churchill Livingstone, Edinburgh.
125. Porter, R. J. and Meldrum, B. S. (1995) Antiepileptic drugs. In: Basic and Clinical Pharmacology, pp. 361-380, Ed. B. G. Katzung. Appleton and Lange, East Norwalk, CT.
126. Rambeck B., Specht U., Wolf P. Pharmacokinetic interactions of the new antiepileptic drugs. Clin. Pharmacokinet. 31:1996;309-324.
127. Ramsay, R. E. (1995) Gabapentin. Toxicity. In: Antiepileptic Drugs, 4th Edn, pp. 857-860, Eds. R. H. Levy, R. H. Mattson and B. S. Meldrum. Raven Press, New York.
128. Reinikainen K.J., Keranen T., Halonen T., Kamulainen H., Riekkinen P.J. Comparison of oxcarbazepine and carbamazepine: a double-blind study. Epilepsy Res. 1:1987;284-289.
129. Richardson E.P., Dodge P.R. Epilepsy in cerebrovascular disease. Epilepsia. 3:1954;49-74.
130. Richens A. (1992) Pharmacokinetics of lamotrigine. In: Clinical Update on Lamotrigine: A Novel Antiepileptic Agent, pp. 22-26, Ed. A. Richens. Wells Medical, Royal Tumbridge Wells, UK.
131. Richens, A. and Perucca, E. (1993) General principles in the drug treatment of epilepsy. In: A Textbook of Epilepsy, 4th Edn, pp. 3-23, Eds. J. Laidlaw, A. Richens and D. Chadwick. Churchill Livingstone, Edinburgh.
132. Richens A., Yuen A.W. C. Overview of the clinical efficacy of lamotrigine. Epilepsia. 32:1991;S13-S16.
133. Riedenberg M.M., Odar-Cederlof I., von Bahr C., Borga O., Sjoqvist F. Protein binding of diphenylhydantoin and desmethylimimpramine in patients with poor renal function. N. Engl. J. Med. 285:1991;264-267.
134. Riley R.J., Kitteringham N.R., Park B.K. Structural requirements for bioactivation of anticonvulsivants to cytoxic metabolites in vitro. Br. J. Clin. Pharmacol. 28:1989;482-487.
135. Rogawski M.A., Porter R.J. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental tage compounds. Pharmacol. Rev. 42:1990;223-286.
136. Romanelli M.F., Morris S.C., Askin K., Coben L.A. Advanced Alzheimer's disease is a risk factor for late onset seizures. Arch. Neurol. 47:1990;847-850.
137. Roskos K.V., Maibach H.I., Guy R.H. The effect of aging on percutaneous absorption in man. J. Pharmacokinet. Biopharm. 17:1989;617-630.
138. Safar M. Ageing and its effects on the cardiovascular system. Drugs. 39:1990;1-8.
139. Schapel G.J., Beran R.G., Vajda F.J. E. Double-blind, placebo-controlled, crossover study of lamotrigine in treatment resistant partial seizures. J. Neurol. Neurosurg. Psychiat. 56:1993;448-453.
140. Scheuer M.L., Cohen J. Seizures and epilepsy in the elderly. Neurol. Clin. 11:1993;787-804.
141. Schmidt, D. (1995) Benzodiazepine. Diazepam. In: Antiepileptic Drugs, 4th Edn, pp. 705-724, Eds. R. H. Levy, R. H. Mattson and B. S. Meldrum. Raven Press, New York.
142. Schwabe S. Clinical development outlook of oxcarbazepine. Epilepsia. 35:1994;S2-S4.
143. Sheridan P.H., Ashworth M., Milne K. Open pilot study of felbalmate (ADD 03055) in partial seizures. Epilepsia. 27:1985;649-650.
144. Sherwin A.L., Loynd J.S., Bock G.W., Sokolwski C.D. Effects of age, sex, obesity and pregnancy on plasma diphenylhydantoin levels. Epilepsia. 15:1974;541-547.
145. Stewart B.H., Kugler A.R., Thompson P.R., Bockbrader H.N. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of lack of proportionality between increasing dose and drug levels in plasma. Pharmacol. Res. 10:1993;276-281.
146. Sung C.Y., Chu N.S. Epileptic seizures in intracerebral hemorrhage. J. Neurol. Neurosurg. Psychiat. 52:1989;1273-1276.
147. Tallis R., Hall G., Craig I., Dean A. How common are epileptic seizures in old age? Age Ageing. 20:1991;442-448.
148. Taylor C.P., Vartanian M.G., Yuen P.W., Bigge C., Suman-Chauhar N., Hill D.R. Potent and stereo-specific anticonvulsant activity of 3-isobutyl GABA relates to in vitro binding at a novel site labeled by tritiated gabapentin. Epilepsy Res. 14:1993;11-15.
149. Theisohn M., Heinmann G. Disposition of the antiepileptic oxcarbazepine and its metabolites in healthy volunteers. Eur. J. Clin. Pharmacol. 22:1982;545-551.
150. The US Gabapentin Study Group n.5 Gabapentin as add-on therapy in refractory partial epilepsy. Neurology. 43:1993;2292-2298.
151. Thomas S.V., Pradeep K.S., Rajmohan S.J. First ever seizures in the elderly: a seven-year follow-up study. Seizure. 6:1997;107-110.
152. Thomson A.H., Brodie M.J. Pharmacokinetic optimisation of anticonvulsant therapy. Clin. Pharmacokinet. 23:1992;216-230.
153. 1-acid-glycoprotein. N. Engl. J. Med. 307:1982;1148.
154. Troupin, A. S. and Johannessen, S. I. (1990) Epilepsy in the elderly. In: Epilepsy: Current Approaches to Diagnosis and Treatment, pp. 141-153, Ed. D. Smith. Raven Press, New York.
155. Umstead G.S., Morales M., McKercher P.L. Comparison of total, free, and salivary phenytoin concentrations in geriatric patients. Clin. Pharmacol. 5:1986;59-62.
156. Verbeeck R.K., Cardinal J.A., Wallace S.M. Effect of age and sex on the plasma binding of acid and basic drugs. Eur. J. Clin. Pharmacol. 27:1984;91-97.
157. Vestal R.E., McGuire E.A., Tobin J.D., Andres R., Norris A.H., Mezey E. Aging and ethanol metabolism. Clin. Pharmacol. Ther. 21:1977;343-354.
158. Vollmer K.O., von Hodenberg A., Kolle E.U. Pharmacokinetics and metabolism of gabapentin in rat, dog and man. Arzneimittelforsch. 36:1986;830-839.
159. Welty D.F., Schielke G.P., Vartanian M.G., Taylor C.P. Gabapentin anticonvulsivant action in rats: disequilibrium with peak drug concentrations in plasma and brain microdialysate. Epilepsy Res. 16:1993;175-181.
160. Wilensky A.J., Friel P.N., Ojemann L.M. Pharmacokinetics of W-544 (ADD03055) in epileptic patients. Epilepsia. 26:1985;602-606.
161. Wilkinson, M. (1979) The effects of aging on the disposition of benzodiazepines in man. In: Drugs and the Elderly, pp. 103-106, Eds. J. Cooks and I. Stevenson. University Park Press, Baltimore, MD.
162. Willmore L.J. The effect of age on pharmacokinetics of antiepileptic drugs. Epilepsia. 36:1995;S14-S21.
163. Willmore L.J. Management of epilepsy in the elderly. Epilepsia. 37:1996;S23-S33.
164. Willmore, L. J. and Dulac, O. (1995) Use of antiepileptic drugs in children and the elderly. In: Antiepileptic Drugs, 4th Edn, pp. 231-242, Eds. R. H. Levy, R. H. Mattson and B. S. Meldrum. Raven Press, New York.
165. Woodburg, D. M. (1980) Antiepileptic drugs: mechanism of action. In: Advanced in Neurology, pp. 249-303. Raven Press, New York.
166. Woodhouse K.W., James O.F. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology. 9:1989;297-301.
167. Woodhouse K.W., James O.F. W. Hepatic drug metabolism and ageing. Br. Med. Bull. 46:1990;22-35.
168. Woodhouse K.W., Wynne H.A. Age related changes in liver size and hepatic blood flow. The influence on drug metabolism in the elderly. Clin. Pharmacokinet. 15:1988;287-294.
169. Wynne H.A., Goudevenos J., Rawlins M.D., James O.F., Adams P.C., Woodhouse K.W. Hepatic clearance: the effect of age using indocyanine green as a model compound. Br. J. Clin. Pharmacol. 30:1990;634-637.
170. Yuen, A. W. C. (1995) Lamotrigine: Interactions with other drugs. In: Antiepileptic Drugs, 4th Edn, pp. 883-887, Eds. R. H. Levy, R. H. Mattson and B. S. Meldrum. Raven Press, New York.